Table 2.

Selected genotyping results. (A) Comparisons relative to NAFLD cases. (B) comparisons relative to sample Bronx population

(A)
Gene	SNP	MAF‐NAFLD cases	MAF‐controls	OR	P‐value	MAF‐Bronx population	OR	P‐value	MAF‐general population	RR	P‐value	MAF‐Puerto Rican population	OR	P‐value
CHUK	rs11597086	26% (22/15/3)	16% (15/7/0)	1.65	0.35	23% (134/75/14)	1.14	0.67	22% (694/308/90)	1.18	0.55	43% (19/25/11)	0.61	0.09
ENPP1	rs1044498	37% (19/11/9)	42% (10/8/6)	0.89	0.72	36% (105/80/42)	1.03	0.90	29% (660/224/208)	1.27	0.29	19% (37/15/3)	1.96	0.05
ERLIN1	rs2862954	29% (20/14/4)	14% (15/6/0)	2.03	0.20	26% (127/69/22)	1.12	0.70	25% (665/314/113)	1.17	0.55	48% (15/27/13)	0.60	0.07
PNPLA3	rs738409	56% (9/17/14)	19% (16/7/1)	2.95	0.003	19% (139/62/8)	3.01	4.4E‐7	28% (590/382/120)	1.97	0.0001	36% (20/30/5)	1.56	0.05
PNPLA3	rs2896019	41% (17/13/10)	17% (17/6/1)	2.48	0.04	25% (132/75/20)	1.63	0.04	28% (604/374/114)	1.50	0.06	28% (27/25/3)	1.47	0.18
SAMM50	rs3761472	38% (17/14/8)	17% (16/8/0)	2.31	0.07	21% (146/68/14)	1.83	0.02	25% (628/374/90)	1.52	0.07	21% (33/21/1)	1.83	0.06
SAMM50	rs2143571	44% (14/16/9)	25% (13/10/1)	1.74	0.14	28% (120/88/20)	1.55	0.05	32% (514/453/125)	1.35	0.14	30% (25/27/3)	1.45	0.18
ABCC2	rs17222723	10% (31/8/0)	2% (23/1/0)	4.92	0.22	7% (193/33/0)	1.40	0.52	4% (1000/91/1)	2.40	0.08	7% (47/8/0)	1.47	0.57

(B)
		MAF‐Bronx population	MAF‐general population	OR	P‐value	MAF‐Puerto Rican population	OR	P‐value
CHUK	rs11597086	23%	22%	1.04	0.79	43%	0.54	0.003
ENPP1	rs1044498	36%	29%	1.24	0.04	19%	1.90	0.02
ERLIN1	rs2862954	26%	25%	1.05	0.69	48%	0.54	1.5E‐3
PNPLA3	rs738409	19%	28%	0.66	3.5E‐3	36%	0.52	5.2E‐4
PNPLA3	rs2896019	25%	28%	0.92	0.49	28%	0.90	0.68
SAMM50	rs3761472	21%	25%	0.83	0.17	21%	1.00	0.98
SAMM50	rs2143571	28%	32%	0.87	0.22	30%	0.94	0.78
ABCC2	rs17222723	7%	4%	1.71	0.05	7%	1.04	0.94

NAFLD, nonalcoholic fatty liver disease; SNP, single‐nucleotide polymorphisms.